A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

NCT05904886 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

687

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Atezolizumab
DRUG: Bevacizumab
DRUG: Tiragolumab
OTHER: Placebo

Sponsor

Hoffmann-La Roche

Collaborators

[object Object]